Drug manufacturer receives unprecedented injunction against the NHS

No items found.
​
17 April 2015
Tags
Litigation
Life

The Journal of Intellectual Property Law and Practice (JIPLP) has published an article by Darren Smyth on a significant series of cases, which included drug manufacturer Warner-Lambert obtaining a court order requiring NHS England to issue guidelines to doctors when prescribing the generic pregabalin for the treatment of neuropathic pain to patients, to prescribe by reference to the brand name Lyrica® and not the generic name pregabalin. The judge also explained the meaning of Swiss-form claims for the first time.

To read the article in full, click here.

Related articles

EIP strengthens Swedish presence with dedicated Malmö office
10 November 2026
EIP has strengthened its presence in Sweden with a dedicated Malmö office, reflecting the continued growth of our team in southern Sweden. The Malmö team supports innovative businesses with intellectual property expertise, helping them protect their ideas and maximise their commercial value.
EIP named in The Times Best Law Firms for a second year running
05 November 2026
EIP have been named in The Times Best Law Firms 2027 and commended for intellectual property, for the second consecutive year.
EIP ranked Band 1 in Chambers UK 2027, with three lawyers also recognised
14 October 2026
Chambers recognised EIP for its patent litigation work and its strength in disputes concerning FRAND licensing and standard essential patents.